Physician profile
Haley Cooper
NPI 1992398333
$3,820.13
in general payments reported to CMS, 2019-2025
32 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $673 · 2023: $675 · 2024: $871 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $828.22 | 2021-2025 | |
| Novo Nordisk INC | $560.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $431.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $383.78 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $215.37 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.02 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $156.38 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $146.30 | 2025 | Zenpep, Vowst |
| Pfizer INC. | $115.99 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.49 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $69.39 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $68.72 | 2021-2023 | |
| Exact Sciences Corporation | $65.44 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $51.38 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $51.36 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.52 | 2022 | |
| Organon LLC | $42.86 | 2025 | Nexplanon |
| Sanofi Pasteur INC. | $38.49 | 2023-2025 | |
| Advanced Respiratory, INC | $36.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.45 | 2021 | |
| Corcept Therapeutics | $32.34 | 2024 | Korlym |
| Shield Therapeutics INC | $29.88 | 2025 | |
| Baxter Healthcare | $29.57 | 2022 | |
| Exeltis, USA INC. | $19.78 | 2025 | Slynd |
| Medtronic, INC. | $18.43 | 2024 | Intellis Adaptivestim |
| Biomarin Pharmaceutical INC. | $17.85 | 2025 | Voxzogo 1.2mg |
| Novartis Pharmaceuticals Corporation | $16.69 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Amgen INC. | $14.51 | 2023 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $13.76 | 2023 | Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $9.00 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $5.18 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.